Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03657043
Title A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Seattle Genetics, Inc.

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer


Tisotumab Vedotin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.